Tianda Pharmaceuticals (HKSE:00455) Other Financing: HK$0.7 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:00455 Tianda Pharmaceuticals Ltd HKSE:00455
24 GF Score
Price HK$0.11
GF Value HK$0.13
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Tianda Pharmaceuticals Other Financing?

Tianda Pharmaceuticals HKSE:00455 -12.60% 24 Other Financing is HK$0.7 Mil as of Dec. 2025. GuruFocus rates HKSE:00455 with a GF Score™ of 24/100 and a GF Value™ of HK$0.13 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Tianda Pharmaceuticals's Other Financing for the six months ended in Dec. 2025 was HK$0.7 Mil.

Tianda Pharmaceuticals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.7 Mil.

Tianda Pharmaceuticals Other Financing Historical Data

* Premium members only.

The historical data trend for Tianda Pharmaceuticals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tianda Pharmaceuticals Other Financing Chart

Tianda Pharmaceuticals Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.94 -0.89 -25.23 0.00 0.68

Tianda Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.68 0.00
HKSE:00455
24GF Score
Tianda Pharmaceuticals Ltd HKSE:00455
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tianda Pharmaceuticals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of HK$0.7 Mil mean?
Tianda Pharmaceuticals (HKSE:00455) has a Other Financing of HK$0.7 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Tianda Pharmaceuticals and its competitors.
Is Tianda Pharmaceuticals' Other Financing too high?
Tianda Pharmaceuticals' current Other Financing is HK$0.7 Mil. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' Other Financing compare to ZTS?
Tianda Pharmaceuticals' Other Financing of HK$0.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Tianda Pharmaceuticals and its competitors. Tianda Pharmaceuticals's current Other Financing is HK$0.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current Other Financing is HK$0.7 Mil. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current Other Financing is HK$0.7 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?

Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued. The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13. GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for HKSE:00455:

  • Other Financing: HK$0.7 Mil
  • GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
  • GF Score™: 24/100 with 3 warning signs

No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tianda Pharmaceuticals Business Description

Address No. 1 Tim Mei Avenue, Suites 2405-2410, 24th Floor, CITIC Tower, Central, Hong Kong, HKG
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score

Get the complete analysis for HKSE:00455

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.11
Price
HK$0.13
GF Value